Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
Lexicon Pharmaceuticals announces three poster presentations at the 84th Scientific Sessions of the American Diabetes Association from June 21-24, 2024, in Orlando, Florida. The presentations will occur on June 23, from 12:30 - 1:30 p.m. ET, focusing on diabetic peripheral neuropathic pain (DPNP) and the efficacy of sotagliflozin. The studies include patient-reported burdens of DPNP, the impact of sotagliflozin as an add-on for inadequately controlled basal insulin-treated type 2 diabetes, and a comparison of sotagliflozin vs. empagliflozin or placebo in type 2 diabetes. This research underscores Lexicon's efforts to address unmet medical needs in diabetes.
- Lexicon Pharmaceuticals is actively participating in a major scientific event, enhancing their visibility in the medical community.
- The company is showcasing three significant research studies, highlighting their ongoing commitment to diabetes treatment.
- Presentation of new data on the efficacy of sotagliflozin, potentially reinforcing the drug's market position and clinical value.
- Patient-reported outcomes provide valuable insights, potentially improving patient-centric treatment approaches.
- No new financial data or direct revenue impacts were reported in the press release.
- The PR does not mention any immediate or short-term market opportunities that would directly affect stock price.
THE WOODLANDS, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 84th Scientific Sessions of the American Diabetes Association being held June 21 - 24, 2024 at the Orange County Convention Center in Orlando, Florida.
All three poster presentations will occur on Sunday, June 23, 12:30 - 1:30 p.m. ET, in the Poster Hall (West A-4-B2). Details are as follows:
- "Patient-Reported Burden of Disease in Diabetic Peripheral Neuropathic Pain—Learnings from In-depth Patient Interviews—Substudy of RELIEF-DPN 1," Board No. 484, presented by Linda M. Gaudiani MD, FACP, FACE, Medical Director and President NorCal Medical Research, Greenbrae, California, Co-Founder Braden Diabetes Center and President Marin Endocrine Care and Research Greenbrae, California
- “Impact of Sotagliflozin, a Dual Sodium–Glucose Cotransporter 1/2 Inhibitor, as Add-on to Inadequately Controlled Basal Insulin–Treated Type 2 Diabetes,” Board No. 924, presented by Julio Rosenstock, MD, Senior Scientific Advisor for Velocity Clinical Research, Director of Velocity’s site at Medical City Dallas, and Clinical Professor of Medicine at the University of Texas Southwestern Medical Center, Dallas, Texas
- “Sotagliflozin vs. Empagliflozin or Placebo in Type 2 Diabetes on a DPP-4i +/- Metformin,” Board No. 917, presented by Anne L. Peters, MD, Professor of Medicine at the Keck School of Medicine of USC, Director of the USC Clinical Diabetes Programs, Los Angeles, California
“The Lexicon-sponsored research to be presented reflect our ongoing commitment to addressing unmet medical needs within the diabetes community,” said Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer. “We are especially appreciative of the people with diabetes who shared their first-hand and deeply personal accounts of the tremendous burdens associated with diabetic peripheral neuropathic pain.”
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has commercially launched one of these medicines, INPEFA® (sotagliflozin) in the United States, and has a pipeline of other promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.
About LX9211
Discovered using Lexicon’s unique approach to gene science, LX9211 is a potent, orally delivered, selective, investigational small molecule inhibitor of adaptor-associated kinase 1 (AAK1). Lexicon identified AAK1 in its target discovery efforts as a promising approach for the treatment of neuropathic pain and identified LX9211 and another development candidate in a neuroscience drug discovery alliance with Bristol-Myers Squibb from which Lexicon holds exclusive development and commercialization rights. Preclinical studies of LX9211 demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways. LX9211 has received Fast Track designation from the U.S. Food and Drug Administration for development in diabetic peripheral neuropathic pain.
About Sotagliflozin
Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). SGLT2 is responsible for glucose and sodium reabsorption by the kidney and SGLT1 is responsible for glucose and sodium absorption in the gastrointestinal tract. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, diabetes, and chronic kidney disease in clinical studies involving approximately 20,000 patients.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize INPEFA in heart failure, conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin (in other indications), LX9211, LX9851 and its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its products and drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2023 and other subsequent disclosure documents filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Investor Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
For Media Inquiries:
Alina Cocuzza
Lexicon Pharmaceuticals, Inc.
acocuzza@lexpharma.com
FAQ
What dates will Lexicon Pharmaceuticals present at the 84th Scientific Sessions of the American Diabetes Association?
When is Lexicon Pharmaceuticals presenting their posters at the American Diabetes Association event?
What topics are covered in Lexicon's presentations at the American Diabetes Association event?
What type of impact does sotagliflozin have on inadequately controlled basal insulin-treated type 2 diabetes?
What is the significance of patient-reported outcomes in Lexicon's research?
Who are the presenters of Lexicon's research at the American Diabetes Association event?
